Buspar
Result: $90 million settlement
Year: 2003
In re Buspirone Antitrust Litigation
In November 2003, Lieff Cabraser obtained a $90 million cash settlement for individual consumers, consumer organizations, and third party payers that purchased BuSpar, a drug prescribed to alleviate symptoms of anxiety.
Plaintiffs alleged that Bristol-Myers Squibb Co. (BMS), Danbury Pharmacal, Inc., Watson Pharmaceuticals, Inc. and Watson Pharma, Inc. entered into an unlawful agreement in restraint of trade under which BMS paid a potential generic manufacturer of BuSpar to drop its challenge to BMS’ patent and refrain from entering the market.
Lieff Cabraser served as Plaintiffs’ Co-Lead Counsel.
Civil Litigation News
Judge Will Grant Preliminary Approval to $255M Economic Loss Settlement Against Juul
As reported by Law360, on January 20, 2023, U.S. District Judge William H. Orrick of the Federal District Court for the Northern District
Consumer Class Action Over Evenflo Child Car Seats to Move Forward
On Wednesday, January 3, 2023, The 1st Circuit Court of Appeal in Boston declined to rehear its November 23rd decision reviving the
Federal Court says Evenflo must face ‘Big Kid’ booster seat safety litigation
The 1st Circuit Court of Appeal in Boston has revived class action litigation accusing Evenflo Company Inc of misleading consumers about the
